Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.

No definition available.

Name:	abbv_LossContingencyIndividualPlaintiffLawsuitsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of generic companies with whom certain litigation related agreements were entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws whose court finding was reversed.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyNumberofGenericCompaniesasCounterpartyofLitigationWhoseCourtFindingWasReversed
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of purported class actions filed, pertaining to a loss contingency during the period.

+ References

No definition available.

+ Details

Name:	abbv_LossContingencyPurportedClassActionsNumber
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Numbers of cases are consolidated for pre-trial purposes.

+ References

No definition available.

+ Details

Name:	abbv_NumberOfCasesConsolidatedForPreTrialPurposes
Namespace Prefix:	abbv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of claims subject to settlement agreements

+ References

No definition available.

+ Details

Name:	abbv_PercentageofClaimsSubjecttoSettlementAgreements
Namespace Prefix:	abbv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of loss contingency liability.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyAccrualAtCarryingValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of damages awarded to the plaintiff in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesAwardedValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of plaintiffs that have filed claims pertaining to a loss contingency.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_DepakoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_DepakoteLitigationInFederalAndStateCourtsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_NiaspanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_AndroGelAntitrustLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=abbv_DisgorgementRemedyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_ElliottAssociatesL.P.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_GenericDrugPricingSecuritiesLitigationInU.S.DistrictCourtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=abbv_TestosteroneReplacementTherapyProductsLiabilityLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=abbv_ClaimsNotBeingSettledInMasterSettlementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Legal Proceedings and Contingencies (Details) $ in Millions	1 Months Ended				9 Months Ended
Legal Proceedings and Contingencies (Details) $ in Millions	Sep. 30, 2020 USD ($) claim company	Jun. 30, 2018 USD ($)	Jun. 30, 2016 investment_fund	Sep. 30, 2014 company	Sep. 30, 2020 USD ($) claim	Sep. 30, 2020 USD ($) claim direct_purchaser	Sep. 30, 2020 USD ($) claim lawsuit	Sep. 30, 2020 USD ($) claim class_action	Sep. 30, 2020 USD ($) claim end_payor_purchaser	Dec. 31, 2019 USD ($)
Legal Proceedings and Contingencies
Recorded accrual balance for litigation \| $	$ 70				$ 70	$ 70	$ 70	$ 70	$ 70	$ 290
Percentage of claims subject to settlement agreements					95.00%
Depakote litigation in the District Court for the Southern District of Illinois
Legal Proceedings and Contingencies
Number of claims pending	120				120	120	120	120	120
Depakote litigation in federal and state courts
Legal Proceedings and Contingencies
Number of claims pending	4				4	4	4	4	4
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit							4
Number of purported class actions \| class_action								2
Number of healthcare benefit providers acting as plaintiff in lawsuit						1			1
AndroGel antitrust litigation
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company				2
Number of generic companies named in claim whose court finding was reversed \| company	1
AndroGel antitrust litigation \| Disgorgement remedy
Legal Proceedings and Contingencies
Damages awarded against company \| $		$ 448
Prescription drug abuse litigation
Legal Proceedings and Contingencies
Number of claims pending	3,050				3,050	3,050	3,050	3,050	3,050
Prescription drug abuse litigation in state courts
Legal Proceedings and Contingencies
Number of claims pending	279				279	279	279	279	279
Elliott Associates, L.P.
Legal Proceedings and Contingencies
Number of parties to lawsuit (in investment funds) \| investment_fund			5
Generic drug pricing securities litigation in U.S. District Court of New Jersey
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit							1
Number of purported class actions \| class_action								3
Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Number of claims pending	175				175	175	175	175	175
Number of claims consolidated for pre-trial purposes	3,500				3,500	3,500	3,500	3,500	3,500
Claims not being settled in master settlement agreement \| Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Number of claims pending	5				5	5	5	5	5